C. trachomatis and herpes simplex virus-2 were both linked to epithelial ovarian cancer.
State-of-the-art advanced imaging coupled with whole-genome sequencing shows utility in early cancer detection and cancer-associated pathogenic variant detection.
In this study, pre- and postsurgical specimens of cell-free DNA from women with newly diagnosed endometrial cancer were subjected to ultra-high depth sequencing.
The search for molecular precursors of cancer in the fallopian tubes is largely driven by emerging evidence supporting it as the site of origin for many ovarian cancers.
This study evaluated the rates of germline and somatic BRCA testing in women with ovarian cancer included in the Flatiron Health database.
PAOLA-1/ENGOT-ov25 is a phase 3 clinical trial evaluating a first-line olaparib plus bevacizumab maintenance regimen in patients with advanced ovarian cancer.
This analysis presents preliminary data for secondary endpoints of TFST and PFS2 from the phase 3 PRIMA/ENGOTOV26/GOG-3012 study.
JAVELIN Ovarian 100 was the first phase 3 study to evaluate an immune checkpoint inhibitor in previously untreated advanced epithelial ovarian cancer.
The insulin-lowering properties of metformin, along with its effects on synthetic metabolism, were some of the rationales for its use as a cancer therapy.
Lenvatinib plus pembrolizumab demonstrated promising antitumor efficacy against recurrent endometrial cancer, which led to its FDA approval.
Findings based on comparison to hormonal intrauterine devices.
Regardless of birthplace, women who are Asian Pacific Islanders appear to have a higher risk of developing ovarian clear cell cancer compared with other ethnicities.
CMS recently announced that patients with germline ovarian or breast cancer would be covered for diagnostic testing that uses next-generation sequencing.
A pervading theme of this guideline was the importance of including genetic counselors in the interpretation and communication of germline and somatic testing results.
Review highlights limitations of trial design; additional research needed to address uncertainties.
A microfluidics platform for engineering activated antigen carrier immunotherapies from red blood cells showed promising preliminary results in a mouse model.
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
Some experts say the talc study’s data limitations weaken its impact in the field.
In this first reported prospective study, researchers compared outcomes of fertility-sparing surgery with radical surgery in women with stage I nonepithelial ovarian cancer.
Germline PALB2 pathogenic variants were associated with an increased risk of female or male breast cancer, as well as ovarian and pancreatic cancer.